Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
March 31, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
February 22, 2022 09:00 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...